Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
116 hedge funds and large institutions have $164M invested in Paratek Pharmaceuticals, Inc. in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 36 increasing their positions, 33 reducing their positions, and 15 closing their positions.
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
8% more funds holding
Funds holding: 107 → 116 (+9)
9% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 33
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $167M → $164M (-$3.09M)
68% less call options, than puts
Call options by funds: $760K | Put options by funds: $2.37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$2.03M |
| 2 |
Millennium Management
New York
|
+$2.02M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.4M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.33M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.7M |
| 2 |
Two Sigma Investments
New York
|
-$2.01M |
| 3 |
Renaissance Technologies
New York
|
-$1.42M |
| 4 |
D.E. Shaw & Co
New York
|
-$887K |
| 5 |
Morgan Stanley
New York
|
-$705K |
PRTK Hedge Fund Activity: Q2 2021 in Review
116 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q2 2021, worth a combined $164M — down 1.8% from $167M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PRTK positions and 15 closed out — a net gain of 9 holders — while 36 added to existing stakes and 33 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $2.03M. The largest seller was BlackRock, cutting an estimated $4.7M.
- 116 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q2 2021, up from 107 in Q1 2021.
- Funds reported $164M of Paratek Pharmaceuticals, Inc. stock for Q2 2021, down 1.8% quarter-over-quarter.
- 24 funds opened new Paratek Pharmaceuticals, Inc. positions in Q2 2021 and 15 closed out, a net change of +9 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q2 2021 was Marshall Wace, an estimated $2.03M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q2 2021 was BlackRock, an estimated $4.7M sold.
Based on aggregated 13F filings for Q2 2021.